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Abstract
The HeartWare HVAD System (Medtronic) is a durable implantable left ventricular assist device that has been implanted in approximately 20,000 patients worldwide for bridge to transplant and destination therapy indications. In December 2020, Medtronic issued
an Urgent Medical Device Communication informing clinicians of a critical device malfunction in which the HVAD may experience a
delay or failure to restart after elective or accidental discontinuation of pump operation. Moreover, evolving retrospective comparative effectiveness studies of patients supported with the HVAD demonstrated a significantly higher risk of stroke and all-cause mortality when compared with a newer generation of a commercially available durable left ventricular assist device. Considering the totality
of this new information on HVAD performance and the availability of an alternate commercially available device, Medtronic halted
the sale and distribution of the HVAD System in June 2021. The decision to remove the HVAD from commercial distribution now
requires the use of the HeartMate 3 left ventricular assist system (Abbott, Inc) if a patient previously implanted with an HVAD
requires a pump exchange. The goal of this document is to review important differences in the design of the HVAD and HeartMate 3
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that are relevant to the medical management of patients supported with these devices, and to assess the technical aspects of an
HVAD-to-HeartMate 3 exchange. This document provides the best available evidence that supports best practices. (J Thorac
Cardiovasc Surg 2022;-:1–8)
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The HeartWare HVAD System (Medtronic) is a durable left ventricular assist device (LVAD) approved for bridge to transplant indication
in 2012 and destination therapy indication in 2019, based on data
from the ADVANCE + Continued Access Protocol, ENDURANCE,
and ENDURANCE Supplemental clinical studies [1–5]. To date, the
device has been implanted in approximately 20,000 patients worldwide and had gained wide adoption, particularly in clinical scenarios
that use a left anterolateral thoracotomy approach for device placement [6], for patients with smaller body size and for off-label pediatric applications [7]. In December 2020, Medtronic issued an Urgent
Medical Device Communication informing clinicians of a critical device malfunction in which the HVAD System may experience a
delay or failure to restart after elective or accidental discontinuation
of pump operation [8]. In addition, mounting evidence from retrospective comparative effectiveness studies demonstrated a significantly higher risk of stroke and all-cause mortality in HVAD
recipients when compared with those receiving a newer generation
of a commercially available durable LVAD, the HeartMate 3 left ventricular assist system (Abbott, Inc) [9–13]. In a recent report, the
HVAD was associated with a higher incidence of major neurologic
adverse events in the late constant hazard phase (hazard ratio, 5.71)
[13] and higher risk of risk of mortality (hazard ratio, 3.20) compared
with the HeartMate 3 device [9]. Considering the totality of new information on HVAD performance, Medtronic halted its sale and distribution in June 2021.
Understandably, numerous concerns and questions have
arisen from clinicians and patients. The most pressing question
is how to treat the patients who remain supported with an
HVAD. In particular, 2 options have been advanced: (1) continue ongoing support with the HVAD, only changing to a
HeartMate 3 “for cause” (ie, pump malfunction or infection); or
(2) electively perform an HVAD-to-HeartMate 3 exchange to
reduce the potential risk of patient harm that may occur from
a device malfunction related to the “failure to restart” mode of
device failure. Current recommendations from Medtronic support the former strategy. Recent analyses from The Society of
Thoracic Surgeons Interagency Registry for Mechanically
Assisted Circulatory Support registry has similarly supported a
“for cause” approach because continued support on a normally
functioning HVAD was associated with less risk than that associated with exchange to a HeartMate 3 [14]. Furthermore, the
early risk of exchange from an HVAD-to-HeartMate 3 was
similar to that of exchange from an HVAD-to-HVAD, suggesting that patients were not disadvantaged by requiring an exchange to the HeartMate 3 [14].

HVAD to HeartMate 3 Pump Exchange: Best Practices for
Surgical Management
Figure 1: With the removal of the HeartWare HVAD System (Medtronic) from
commercial distribution, the HeartMate 3 (Abbott, Inc) left ventricular assist
system is now the only commercially available durable left ventricular assist device device to exchange for an HVAD in the event of a need to exchange an
HVAD device.

The decision to remove the HVAD from commercial distribution
now requires surgeons to use the HeartMate 3 as the only commercially available device for primary implantation as well as for
exchanging a previously implanted HVAD (Figures 1 and 2). The
goal of this document is to (1) highlight differences in the design of
the HVAD and HeartMate 3 that are relevant to patient management; and (2) review the surgical management of an HVAD-toHeartMate 3 exchange. This document provides the best available
evidence and consensus opinion that support best practices.

MATERIALS AND METHODS
Differences in Device Design and Implications for
Medical Management
Both pumps are continuous-flow LVADs with centrifugal flow
design [15,16]. The HVAD uses a hybrid engineering design to
levitate the internal impeller with passive magnetic levitation
and a hydrodynamic bearing. It incorporates an optional proprietary pump speed management algorithm, termed the
“Lavare Cycle,” [17] that is designed to reduce pump and ventricular blood stasis and improve washout. The HeartMate 3 is
designed with complete magnetic levitation of the internal impeller that permits greater distances between the motor housing and the impeller compared with the gaps that can be
achieved with a hydrodynamic bearing. Its pump operation
includes an obligatory change in pump speed that achieves a
reduction in flow stagnation in the pump [18]. Recent data
have suggested that the 2 pumps significantly differ in the
rates of hemocompatibility-related adverse events, particularly
with respect to stroke [9–13]. Whether these dissimilarities are
related to the differences in pump design or their dynamic
pump speed modulation algorithms remains unknown.
Additional features of the HVAD include a real-time display of
pump waveforms on the HeartWare monitor that depict the
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Figure 2: Pump exchange of a HeartWare HVAD to HeartMate 3 LVAD. Exchange of the HVAD device should be performed only “for cause,” for example, pump malfunction. The assessment of the surgical risks of the procedure should determine the surgical approach and technique for the exchange procedure. Removal of all
HVAD device components including sewing ring and outflow graft is the optimal technique when feasible and safe. Alternative approaches are available, including
minimally invasive techniques.

variability of blood flow through the pump and the ongoing collection of pump parameters and performance data in the Controller
logfiles. Information gleaned from logfiles, when used in combination with clinical data and assessment, provides critical information
on pump performance to support clinical decision making [19]. The
HeartMate 3 uses the HeartMate Touch Communication System
that provides clinicians with the ability to wirelessly monitor the
HeartMate 3 system, program system parameters such as pump
speed, assess and track alarm conditions, and view and save performance data. The Touch Communication System provides data
on pump speed, pump power, pump flow, and pulsatility index.

experienced a stroke with the HVAD device compared with
12.1% of patients with the HeartMate II device [5].
Antithrombotic recommendations for the HeartMate 3 are based
on the clinical experience from the MOMENTUM 3 and HeartMate
3 Conformite Europeenne Mark clinical studies [22–25]. It calls for
warfarin anticoagulation with an international normalized ratio targeted to 2.0 to 3.0 and antiplatelet therapy with aspirin 81 mg daily.
In the MOMENTUM 3 clinical study, 9.9% of patients receiving the
HeartMate 3 experienced a stroke compared with 19.4% receiving
the HeartMate II [22]. The safety of discontinuing aspirin therapy is
currently being evaluated in a multicenter, prospective, randomized,
double-blinded clinical trial [23].

Patient Management
It is important to note that anticoagulation, antiplatelet, and
blood pressure (BP) management recommendations for the
HVAD System have not been altered as a result of the HVAD device recall.

Anticoagulation and Antiplatelet Management
Antithrombotic recommendations for the HVAD are based on
clinical experience in the ADVANCE + Continued Access Protocol
[1,3], ENDURANCE [4], and ENDURANCE Supplemental clinical
studies [5]. Recommended antithrombotic therapy included warfarin anticoagulation targeted to an international normalized
ratio of 2.0 to 3.0 as well as antiplatelet therapy with aspirin at
more than 81 mg daily. Initial aspirin dosing of 81 mg was associated with an increased risk of pump thrombosis and stroke
[20,21]. In ENDURANCE, 29.7% of patients experienced a stroke
with the HVAD device compared with 12.1% of patients receiving
the comparator device, the HeartMate II (Abbott Labs) [4]. In the
ENDURANCE Supplemental clinical study, 14.7% of patients

Blood Pressure Management
BP management is important for both HVAD and HeartMate 3
devices because continuous-flow devices are afterload
sensitive and designed to optimally perform within a narrow
range of BP. Data from the ENDURANCE Supplemental clinical
study demonstrated that an enhanced BP protocol significantly
reduced mean arterial pressure (MAP) and reduced the overall
stroke rate by 24.2%, with a 50% reduction in hemorrhagic
strokes compared with the original ENDURANCE clinical study
in which said protocol was absent [4,5]. Current recommendations for BP management for HVAD recipients include a target
MAP less than 85 mm Hg if the patient has a palpable pulse or
less than 90 mm Hg if the patient does not have a palpable
pulse [5,26]. A manual cuff and Doppler is the preferred
method for measuring BP.
Conversely, BP management for patients supported by the
HeartMate 3 is less well defined. Patients supported on the
HeartMate 3 should be maintained with a MAP between 80 and
90 mm Hg unless symptoms of lightheadedness, poor organ
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Table 1:

Medical management: Best practices recommendations

Anticoagulation

• Patients supported on the HVAD and the HeartMate 3 should be maintained on warfarin anticoagulation with a target international normalized ratio of 2.0 to
3.0
Antiplatelet therapy
• Patients supported on the HVAD should be maintained on antiplatelet therapy with aspirin at a dose of >81 mg/d
• Patients supported on the HeartMate 3 should be maintained on antiplatelet therapy with aspirin 81 mg/d
Device Management and Monitoring

• For the HVAD, clinicians should continue to monitor waveforms in ambulatory and inpatient settings and use Autologs/HVADLogs to better understand pump
performance and to support clinical decision making, including evaluation of suspected pump thrombus, suction events, and so forth. The Autologs report provides detailed information and trends regarding pump speed/flow/power, medium and high priority alarms, power source data, and system setting changes
• For the HeartMate 3, clinicians should continue to monitor pump parameters on a routine basis to assess changes in pump parameters
• For both devices, it is important to assess the clinical condition of the patient in addition to assessing pump parameters
BP, Blood pressure; MAP, mean arterial pressure

perfusion, or other symptoms due to low pressure supervene,
thereby mandating a higher MAP goal. The risk of hemorrhagic
stroke with higher BP goals has not been definitively established
as with the HVAD. It is thought that the artificial pulse algorithm
used in the HeartMate 3 may cause inaccuracies in determination of MAP, causing clinicians to overestimate actual MAP [27]
(Table 1).

Surgical Considerations for Left Ventricular Assist
Device Pump Exchange
The global risk associated with LVAD exchange is often related to
the preoperative status of the patient and is also driven by the
reasons for the exchange procedure. A recent systematic review
estimated the risk of 30-day mortality for pump exchange in the
setting of changing devices was approximately 10% but varied by
pump type [28]. In addition to pump failure, comorbidities may
include right ventricular failure, hepatic or renal dysfunction, a
history of prior stroke, and ongoing hemolysis, coagulopathy,
and platelet dysfunction. All these comorbidities should be considered when deciding on the operative method of exchange.
Preoperative medical management should include (1) discontinuation of long-acting agents that may suppress the sympathetic
nervous system (eg, beta-blockers, angiotensin receptor neprilysin inhibitor/angiotensin-converting enzyme inhibitor) to reduce
risk of vasoplegia; (2) optimization of right ventricular function
with inotropes, diuretics, or temporary mechanical support; and
(3) optimization of hemostatic function.
First, the appropriate position and angle of the HVAD inflow
cannula must be determined using transesophageal echocardiography or cross-sectional contrast study to assess inflow cannula
position within the left ventricular chamber. If malposition of the
inflow cannula is present, all components of the HVAD sewing
ring should be removed and the new HeartMate 3 sewing ring

should be attached to the apex. The inflow cannula position of
the HeartMate 3 pump can then be optimized with transesophageal echocardiography guidance and traction sutures
placed from the pump to the chest wall or adjusting the length
of the outflow graft. Generous dissection to free adhesions of the
heart may be necessary to permit apical traction to optimize inflow cannula alignment. Extending the pericardial incision, creating a small preperitoneal space at the left ventricular apex, or
opening the left pleura may aid in accommodating the larger
HeartMate 3 pump housing to ensure proper inflow cannula
alignment.

HVAD-to-HeartMate 3 Device Exchange
There are several important technical aspects of the exchange
procedure to consider (Figure 3; Figures E1-E3; Video 1). First is
the difference in size and design of the apical connector/sewing
ring between the 2 systems. Second is the discrepancy of the outflow graft diameter between the 2 systems. Third is the surgical
approach for device exchange: sternotomy versus anterolateral
thoracotomy. For surgeons with appropriate experience in alternative approaches, an anterolateral thoracotomy approach can
be used to prevent injury to cardiac structures or damage to the
outflow graft if adherent to the posterior sternal table.

Apical sewing ring/connectors. The apical sewing ring of
the HVAD differs significantly from that of the HeartMate 3
(Figures E4 and E5). The diameter, including the sewing cuff of
the HVAD sewing ring, measures 43 mm in size. The inflow cannula of the HVAD measures 25 mm from the “O” ring to cannula
tip and 32.3 mm from pump housing to cannula tip with a 21mm outer diameter. The HVAD pump is fabricated of smooth titanium with sintering halfway up and contains a silicone O-ring
to ensure a seal with the sewing ring. The HVAD inflow cannula
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BP management
• BP management goals should be individualized to the patient’s condition. Patients and caregivers should be trained to obtain BP readings and record values before index hospital discharge and should be provided specific MAP targets to notify their clinician for possible intervention
• For patients supported with an HVAD without a palpable pulse, a manual cuff and Doppler is the preferred method for measuring BP with a MAP targeting
<90 mm Hg
• For HVAD patients with a palpable pulse, MAP targets should be <85 mm Hg
• The target goals for BP management for patients supported with the HeartMate 3 are not as well established as those for the HVAD. Patients supported on the
HeartMate 3 should be maintained with a MAP between 80 and 90 mm Hg unless this BP goal is associated with symptoms of lightheadedness, poor organ perfusion, or other symptoms due to low pressure in which a higher BP goal should be established. The risk of hemorrhagic stroke with higher BP goals has not
been definitively established as with the HVAD
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Figure 3: Comparison of the pump dimensions and size for the HeartMate 3 and HeartWare HVAD System. A, The differences in length of the cannula and height of
the pump housing. B, The pump weights and cannula lengths for the HeartMate 3 and HVAD. The diameter of the inflow cannula of the HVAD is approximately 20.6
mm, and the diameter of the HeartMate 3 inflow cannula is 20.5 mm. The length of the sintering along the inflow cannula is approximately 11.7 mm for the HVAD
and approximately 22 mm for the HeartMate 3. The photographs are courtesy of Angela Lorts, MD, MBA, Cincinnati Children’s Hospital Medical Center, Cincinnati,
Ohio. LVAD, Left ventricular assist device.

Video 1: The surgical procedure to exchange the HVAD LVAD to the
HeartMate 3 LVAD. The steps and surgical techniques of the operative procedure for exchange of an HVAD to HeartMate 3 are reviewed. Provided by Dr
Diyar Saeed, Department of Cardiac Surgery at the Leipzig Heart Center. Video
available in the supplementary material.

has a larger diameter compared with the inflow cannula of the
HeartMate 3 [16]. The HVAD sewing ring is constructed of titanium and Dacron polyester and secures the pump inflow cannula
in position with the aid of a torque wrench. The inner portion of
the metallic sewing ring is a C-clamp that can be adjusted by
turning a screw inside the clamp to secure the base of pump’s inflow cannula for optimal placement of the inflow cannula.
The HeartMate 3 device has 2 choices for apical connectors:
a larger size sewing ring with metal housing to maintain a flat
geometry of the felt sewing cuff and a second, smaller design
in which the metal housing has been removed and the size of
the felt sewing ring is reduced in size (Figure E5). The
HeartMate 3 inflow cannula measures 22 mm in length from
the pump housing to cannula tip and 20 mm in external diameter. The outer diameter of the inflow cannula for the
HeartMate 3 is smaller than that of the HVAD and measures
only 20.5 mm (this dimension includes the sintering surface)
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Alternative surgical techniques for securing the HeartMate
3 to the left ventricular apex. Other options for securing the

Outflow graft.

The HeartMate 3 sewing ring can be sewn to the left ventricle
over the existing HVAD sewing cuff. This is feasible because the sewing ring of the HeartMate 3 is larger. This approach reduces surgical
time because it obviates the amount of dissection needed to remove the existing HVAD apical sewing ring. However, hemostasis of
this approach must be ensured and may be more technically difficult to achieve compared with full excision and replacement of the
existing HVAD sewing ring. Moreover, this technique reduces the
depth of insertion of the HeartMate 3 inflow cannula into the left
ventricular cavity, a configuration with unknown sequelae (ie,
hemocompatibility-related adverse events). Alternatively, the metal
connector portion of the HVAD sewing ring can be removed while
leaving only the fabric portion of the sewing ring. This technique
can reduce operative time and potentially have less effect on the
depth of insertion of the HeartMate 3 inflow cannula.

The outflow grafts of the HVAD and HeartMate
3 differ in diameter, measuring 10 mm and 14 mm, respectively
(Figure E7). This difference in outflow graft diameter has important
implications in the exchange procedure and recommendations for
best practices. During the exchange procedure, complete removal
of the HVAD outflow graft would eliminate the concern for discrepancy in outflow graft sizes. Suturing of the HeartMate 3 outflow
graft to a remnant of the HVAD outflow graft will necessitate a significant reduction in outflow graft diameter at the anastomosis or
distal to it. This reduction in size would increase afterload to the
HeartMate 3 [32] (Figure E8). The long-term consequences of this
increase in afterload to the HeartMate 3 are unknown and may potentially increase the risk of hemocompatibility-related adverse
events or result in inadequate left ventricular unloading and manifestations of heart failure. In vitro studies suggest that suturing the
14-mm outflow graft of the HeartMate 3 to varying lengths of remnants of the HVAD 10-mm outflow graft increases afterload to the
HeartMate 3 [32]. Additional data suggest that this added resistance
may be overcome by adjustment of pump speed [32]. The unknown
clinical consequences of higher rotor speeds on hemocompatibility
risks, battery runtime, and pump performance with retention of an
HVAD remnant should be balanced against other procedural
considerations.

Exchange procedure.

The technique for exchange that is most
consistent with the HeartMate 3 Instructions for Use [31] is to completely excise the preexisting HVAD sewing ring and replace it with
a new apical connector specific to the HeartMate 3 device
(Figure E9). Use of circulatory support with cardiopulmonary bypass
or extracorporeal membrane oxygenation is recommended for the
exchange procedure to allow inspection of the left ventricular cavity
and to ensure that the pannus and left ventricular thrombus are
completely removed (Figure E10). The HeartMate 3 apical connector can then be sewn to the left ventricular apex using a series of
interrupted, pledgetted, horizontal mattress sutures (12 individual
sutures) for the standard cuff (Figure E11). Alternatively, 4 pledgetted
sutures followed by a running polypropylene suture can be used to
obtain a secure attachment of the “mini” apical connector to the left
ventricular apex.
In addition to removal of the HVAD sewing ring, complete removal of the outflow graft with enlargement of the aortotomy to
accommodate the 14-mm outflow graft of the HeartMate 3 completely eliminates the discrepancy in outflow graft size mismatch
(Figure E12). This technique will prevent a pressure drop across
the reduced size HVAD outflow graft and avoid an increase in
afterload to the HeartMate 3. However, other procedural considerations must be weighed, including the additional complexity of
having to clamp the ascending aorta partially or fully. Moreover,
the use a left anterolateral thoracotomy approach often requires
using a remnant of the HVAD outflow graft [33,34].

HeartMate 3 to the left ventricular apex have been advanced
[29,30,33,34]. Each has important potential benefits and limitations. If full sternotomy or complete replacement of the HVAD
sewing ring with the HeartMate 3 apical connector poses unacceptable risk as assessed by the surgical team, the following
modifications can be considered [29,30].

A. Implantation of the HeartMate 3 by sewing the HeartMate 3
apical connector over the existing HVAD sewing ring

B. Implantation of the HeartMate 3 using the existing apical
sewing ring of the HVAD system
For the implantation of the HeartMate 3 inflow cannula into
the remaining HVAD metallic sewing ring, a sterile rubber seal
can be placed around the inflow cannula of the HeartMate 3 to
avoid leakage between the HVAD metallic sewing ring and the
inflow cannula of the HeartMate 3 [29,30,33,34] (Figure E6). The
inflow cannula of the new HeartMate 3 can then be placed into
the established HVAD metallic sewing ring, and the screw of the
HVAD sewing ring can be tightened. The advantage of this technique is the reduction in the time needed to replace the HVAD
sewing ring and extent of apical dissection. However, if a reliable
seal is not obtained, bleeding and potential for pseudoaneurysm
formation could occur.

Anterolateral left thoracotomy approach versus sternotomy
approach. An anterolateral left thoracotomy approach may
offer several advantages to the redo-sternotomy approach for
device exchange [33,34]. In view of the larger dimensions of the
HeartMate 3, a wider incision is generally required when using
an anterolateral thoracotomy approach [33]. A major limitation
of this approach is that a longer remnant of the HVAD outflow
graft is left in place because the graft-to-graft anastomosis is typically performed over the acute margin of the right ventricle just
behind the sternum. As suggested, this could significantly increase afterload to the HeartMate 3 and necessitate increasing
the pump speed of the HeartMate 3 to accommodate the increase in resistance [32]. A preoperative computed tomography
angiogram should be obtained to exclude luminal thrombus or
extra-luminal compression or kinking of distal segments of the
retained HVAD outflow graft. Alternatively, a right upper anterior
thoracotomy, tunneling the HeartMate 3 outflow graft through
the right chest, and anastomosis to the ascending aorta at the
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compared with 20.6 mm for the outside diameter of the HVAD
inflow cannula [15,16]. Thus, the inlet cannula of the
HeartMate 3 cannot simply be placed through the HVAD metallic sewing ring and obtain a hemostatic seal and requires
deviations from the HeartMate 3 implant technique as developed in the MOMENTUM 3 clinical study and described in the
HeartMate 3 Instructions for Use [29–31]. Previous reports
have described use of a rubber seal to obtain hemostasis at
the inflow connection [29,30] (Figure E6). The long-term consequences of using an improvised seal are unknown.
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Surgical management: Best practices recommendations

Technique for exchange

• Under optimal clinical scenarios, an HVAD-to-HeartMate 3 exchange should include removal all components of the HVAD device and the apical sewing cuff
of the HeartMate 3 device is sewn to the apex of the left ventricle. The outflow graft of the HVAD System is completely removed to reduce the discrepancy in
outflow graft diameter between the 2 systems
• It is both safe and feasible to implant a HeartMate 3 device through an anterolateral thoracotomy approach. However, this technique does not address the
issue of discrepancy in size of the outflow graft between the 2 LVAD systems. An upper right anterior thoracotomy or an upper hemi-sternotomy incision to
tunnel the HeartMate 3 outflow graft through the right chest to anastomose to the ascending aorta may be added to the anterolateral thoracotomy approach
for device exchange to exclude all remaining remnants of the HVAD outflow graft. This technique must be balanced against using a remnant of the HVAD outflow graft
• Alternative approaches may be considered, if in the opinion of the surgical team, complete excision of all HVAD components poses a unacceptable surgical
risk
LVAD, Left ventricular assist device.

site of the previous HVAD outflow graft can be considered. This
technique, although adding an additional incision and complexity, can completely exclude all the HVAD outflow graft. Less desirable alternatives to exclude the HVAD outflow graft include
anastomosis of the HeartMate 3 outflow graft to the descending
thoracic aorta or the subclavian artery, although these would require leaving a blind HVAD outflow graft in place. Data on the
safety of these approaches are not available (Table 2).

CONCLUSIONS
This document outlines important differences that exist in both patient management and techniques for surgical exchange of an
HVAD-to-HeartMate 3 exchange. Current data support the recommendation that patients supported with a normally functioning
HVAD should remain on support and only undergo exchange “for
cause” because the risk of death due to device exchange likely
exceeds the risk of death remaining on a normally functioning
HVAD device. It is likely that future analyses of data from registries
of durable LVAD devices will be performed to continue to monitor
evidence to support any changes to this recommendation.
Preferably, patients requiring an HVAD-to-HeartMate 3 exchange
should undergo removal of all HVAD system components and replacement with HeartMate 3 components unless, in the opinion of
the surgical team, this approach poses unacceptable risk, in which
case, alternative procedures that reduce the extent of dissection and
reduce surgical time can be used.

SUPPLEMENTARY MATERIAL
Supplementary material is available at EJCTS online.
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Indication for exchange
• Current data do not support “elective” HVAD-to-HeartMate 3 exchange to reduce the potential risk of adverse events arising from a failure to restart device
malfunction [11]. Exchange from an HVAD-to-HeartMate 3 should be performed only “for cause” (ie, device thrombosis or device electrical failure, or device
infection not responsive to medical management)
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